Succinimides Chemische Eigenschaften,Einsatz,Produktion Methoden
Mechanism of action
Succinimides suppress the paroxysmal 3-Hz spike-and-wave activity associated with the lapses of consciousness associated
with absence (petite mal) seizures, thus reducing the frequency of seizures and raising the threshold to seizures. The proposed
mechanism of action involves a decrease in T-type calcium channel activity.
Succinimides are indicated for the monotherapy of absence seizures or with concomitant therapy when additional forms of
seizures occur in combination with absence seizures. These drugs are readily absorbed from the gastrointestinal tract and
display very low protein binding. The drug interactions for the succinimides are less extensive than with the oxazolidinediones.
They may increase plasma phenytoin levels, decrease plasma primidone levels, and either increase or decrease valproate
levels, although the changes may not be clinically significant.
Clinical Use
The clinically used succinimides
include ethosuximide, methsuximide, and phensuximide, which were introduced between 1951 and 1958 and widely
accepted for the treatment of absence seizures.
Succinimides Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte